Clostridium difficile infection: The Present and the Future

Size: px
Start display at page:

Download "Clostridium difficile infection: The Present and the Future"

Transcription

1 Clostridium difficile infection: The Present and the Future Carlos E. Figueroa Castro, MD Assistant Professor, Division of Infectious Diseases Medical College of Wisconsin November 2014

2 I have made this presentation longer than usual, because I lack the time to make it short. Inspired by Blaise Pascal

3

4 Faculty Disclosure Nothing to disclose

5 Objectives Briefly review the latest SHEA/IDSA C.difficile infection (CDI) management guideline Review treatments in active development against CDI Speculate about the treatment of CDI in the next fifty years

6 Why talking about C.difficile? Leading cause of hospital-acquired infections Increased morbidity and mortality Increase in length of stay and care costs Emerging infection in the community setting

7 Rates of US short-stay hospital discharges with Clostridium difficile listed as any diagnosis, by age McDonald LC, Owings M, Jernigan DB. Emerg Infect Dis. 2006;12(3):409-15

8 Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe Warny M et al. Lancet 2005;366:

9 DOI: /

10 General Principles: Testing Do Test in unformed stool only Do not Repeat test during treatment Test asymptomatic patients Obtain test after treatment

11 General Principles: Infection Control Contact isolation for everyone Hand hygiene with soap and water Private room or cohorting Clean with bleach or sporicidal agents

12 General Principles: Treatment Minimize antibiotic use Antimicrobial stewardship program Clinical presentation guides choice of treatment Avoid prolonged metronidazole use Do not use cholestyramine

13 Treatment of C.difficile infection Severity of Infection Treatment Mild to Moderate Severe Severe, complicated Metronidazole 500mg po three times a day for 14 days Oral vancomycin 125mg po four times a day for 14 days Oral vancomycin plus IV metronidazole Vancomycin retention enema Surgical evaluation

14 Acquisition of toxigenic C.difficile in the community Stop unnecessary antimicrobial use Barrier precautions Environmental cleaning Vaccines Monoclonal antibodies Gerding DN, Johnson S. Clin Infect Dis. 2010;51(11):

15 Treatment Options for C.difficile Infection Approved by FDA Off-label Use New Drugs Biotherapeutics Vancomycin Metronidazole Fidaxomicin Rifaximin Nitazoxanide Tigecycline LFF571 (Novartis) Surotomycin (CB-183, 315, Cubist) SMT (Summit) Cadazolid (ACT , Actelion) Oritavancin (LY333328, The Medicines Company) Cholate meta-benzene sulfonic derivative (CamSA) Fecal microbiota transplantation VP (Viropharma) Probiotics IVIG Monoclonal antibodies Vaccines

16

17

18 Rates of Cure without Relapse for Recurrent Clostridium difficile Infection Interventions: Vancomycin, bowel lavage, donor feces Vancomycin, bowel lavage Vancomycin Primary end point: Resolution of diarrhea without relapse after 10 weeks van Nood E et al. N Engl J Med 2013;368:

19

20 Oral, Capsulized, Frozen Fecal Microbiota Transplantation for Relapsing Clostridium difficile Infection Twenty patients (median: 64.5 years; range: 11-89) At least 3 episodes of mild to moderate C.difficile infection or 2 episodes of severe infection 15 capsules in 2 consecutive days Open-label,single-group,preliminary feasibility study Youngster I, JAMA [Internet]. 2014; Available from: +

21 Oral, Capsulized, Frozen Fecal Microbiota Transplantation for Relapsing Clostridium difficile Infection Results: No adverse effects Decline in bowel movements Better self-ranked health scores Patient requiring retreatment had a lower pre-treatment health score Youngster I, JAMA [Internet]. 2014; Available from: +

22

23

24

25

26 Wired s Guide to Crafting the Perfect TED talk

27 Conclusions C.difficile infection is an important pathogen in both the hospital and the community Use the SHEA/IDSA guideline as a starting point to improve quality of care Future advances are linked to a deeper understanding of the human gut microbiome

Overview of C. difficile infections. Kurt B. Stevenson, MD MPH Professor Division of Infectious Diseases

Overview of C. difficile infections. Kurt B. Stevenson, MD MPH Professor Division of Infectious Diseases Overview of C. difficile infections Kurt B. Stevenson, MD MPH Professor Division of Infectious Diseases Conflicts of Interest I have no financial conflicts of interest related to this topic and presentation.

More information

Clostridium Difficile Infection (CDI) Alistair McGregor Hobart Pathology Royal Hobart Hospital TIPCU

Clostridium Difficile Infection (CDI) Alistair McGregor Hobart Pathology Royal Hobart Hospital TIPCU Clostridium Difficile Infection (CDI) Alistair McGregor Hobart Pathology Royal Hobart Hospital TIPCU Disclosures I am not Tom Riley The Fidaxomicin guys brought me dinner once Outline ASID/AICA position

More information

Inappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012

Inappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012 Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton

More information

Clostridium difficile Colitis

Clostridium difficile Colitis Update on Clostridium difficile Colitis Fredrick M. Abrahamian, D.O., FACEP Associate Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA

More information

Reply to Fabre et. al

Reply to Fabre et. al Reply to Fabre et. al L. Clifford McDonald, 1 Stuart Johnson, 2,3 Johan S. Bakken, 4 Kevin W. Garey, 5 Ciaran Kelly, 6 Dale N. Gerding, 2 1 Centers for Disease Control and Prevention, Atlanta, Georgia;

More information

11/2/2015. Update on the Treatment of Clostridium difficile Infections. Disclosure. Objectives

11/2/2015. Update on the Treatment of Clostridium difficile Infections. Disclosure. Objectives Update on the Treatment of Clostridium difficile Infections Spencer H. Durham, Pharm.D.,BCPS (AQ-ID) Assistant Clinical Professor of Pharmacy Practice Auburn University Harrison School of Pharmacy Kurt

More information

Clostridium difficile Infection Prevention. Basics of Infection Prevention 2-Day Mini-Course 2012

Clostridium difficile Infection Prevention. Basics of Infection Prevention 2-Day Mini-Course 2012 Clostridium difficile Infection Prevention Basics of Infection Prevention 2-Day Mini-Course 2012 2 Objectives Describe the etiology and epidemiology of C. difficile infection (CDI) Review evidence-based

More information

Learning Objectives 6/1/18

Learning Objectives 6/1/18 Gulf Coast Multidisciplinary Pharmacotherapy Conference Kelly R. Reveles, PharmD, PhD, BCPS College of Pharmacy, The University of Texas at Austin School of Medicine, UT Health San Antonio Email: kdaniels46@utexas.edu

More information

Clostridium difficile: Review of Treatment & Prevention through Antimicrobial Stewardship

Clostridium difficile: Review of Treatment & Prevention through Antimicrobial Stewardship Clostridium difficile: Review of Treatment & Prevention through Antimicrobial Stewardship Kim Van Wyk, Pharm.D., BCPS Mountain-Pacific Quality Health Objectives Review epidemiology of Clostridium diffilcile

More information

Solving the Mysteries of C. difficile Infection

Solving the Mysteries of C. difficile Infection Solving the Mysteries of C. difficile Infection Kevin W. Garey, PharmD, MS, FSHP Professor and Chair Dept of Pharmacy Practice and Translational Research Disclosures Research grant support paid to the

More information

Preventing Clostridium difficile Infection (CDI)

Preventing Clostridium difficile Infection (CDI) 1 Preventing Clostridium difficile Infection (CDI) All Hands on Deck to Reduce CDI Skill Nursing Facility Conference July 28, 2017 Idamae Kennedy, MPH,BSN,RN,CIC Liaison Infection Preventionist Healthcare

More information

Clostridium Difficile Primer: Disease, Risk, & Mitigation

Clostridium Difficile Primer: Disease, Risk, & Mitigation Clostridium Difficile Primer: Disease, Risk, & Mitigation KALVIN YU, M.D. CHIEF INTEGRATION OFFICER, SCPMG/SCAL KAISER PERMANENTE ASSOCIATE PROFESSOR INFECTIOUS DISEASE, COLLEGE OF GLOBAL PUBLIC HEALTH,

More information

by author The year in Infectious Diseases 24th European Congress of Clinical Microbiology and Infectious Diseases Barcelona, May, 2014

by author The year in Infectious Diseases 24th European Congress of Clinical Microbiology and Infectious Diseases Barcelona, May, 2014 24th European Congress of Clinical Microbiology and Infectious Diseases Barcelona, 10-13 May, 2014 The year in Infectious Diseases Pierluigi Viale Infectious Disease Unit - Teaching Hospital S. Orsola

More information

Clostridium difficile Colitis

Clostridium difficile Colitis 1 Clostridium difficile Colitis William R. Sonnenberg, MD 2 Disclosure Dr. Sonnenberg has no conflict of interest, financial agreement, or working affiliation with any group or organization. 3 Learning

More information

LINEE GUIDA: VALORI E LIMITI

LINEE GUIDA: VALORI E LIMITI Ferrara 28 novembre 2014 LINEE GUIDA: VALORI E LIMITI Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi EVIDENCE BIASED GERIATRIC MEDICINE Older patients with comorbid conditions

More information

Should we test Clostridium difficile for antimicrobial resistance? by author

Should we test Clostridium difficile for antimicrobial resistance? by author Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first

More information

Clinical Spectrum of Disease. Clinical Features. Risk Factors. Risk of CDAD According to Antibiotic Class. Fluoroquinolones as Risk Factor for CDAD

Clinical Spectrum of Disease. Clinical Features. Risk Factors. Risk of CDAD According to Antibiotic Class. Fluoroquinolones as Risk Factor for CDAD Clinical Features Range from mild diarrhea to severe colitis and death Common clinical symptoms include Watery diarrhea Fever Loss of appetite Nausea Abdominal pain/tenderness Less common ileus CDC Fact

More information

SOFT Movement Survey of FMT Programs

SOFT Movement Survey of FMT Programs Appendix 1 (as supplied by the authors): Survey SOFT Movement Survey of FMT Programs Part 1: General Information about your Fecal Microbiota Transplant (FMT) Program 1) Please fill out the information

More information

CDI Management in Post-Acute Care: Part 1

CDI Management in Post-Acute Care: Part 1 CDI Management in Post-Acute Care: Part 1 Robin Jump, MD, PhD VISN10 Geriatric Research Education and Clinical Center (GRECC) Louis Stokes Cleveland VA Medical Center Case Western Reserve University Robin.Jump@va.gov

More information

Section 10: Antimicrobial Stewardship and Clostridium difficile Infection: A Primer for the Infection Preventionist

Section 10: Antimicrobial Stewardship and Clostridium difficile Infection: A Primer for the Infection Preventionist Section 10: Antimicrobial Stewardship and Clostridium difficile Infection: A Primer for the Infection Preventionist Antimicrobial stewardship may be a relatively new addition to the job responsibilities

More information

Educational Module for Nursing Assistants in Long-term Care Facilities: Preventing and Managing Clostridium difficile Infections

Educational Module for Nursing Assistants in Long-term Care Facilities: Preventing and Managing Clostridium difficile Infections Educational Module for Nursing Assistants in Long-term Care Facilities: Preventing and Managing Clostridium difficile Infections Minnesota Department of Health Infectious Disease Epidemiology, Prevention,

More information

Clostridium difficile Infection: An Update on the Current State of Prevention

Clostridium difficile Infection: An Update on the Current State of Prevention Intermountain APIC and Qualis Health present I-APIC HAI Prevention Learning Network Webinar Series Clostridium difficile Infection An Update on the April 11, 2012 Ruth CarricoPhD RN FSHEA CIC Clostridium

More information

Preventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal

Preventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal Preventing Multi-Drug Resistant Organism (MDRO) Infections For National Patient Safety Goal 07.03.01 2009 Methicillin Resistant Staphlococcus aureus (MRSA) About 3-8% of the population at large is a carrier

More information

Antibiotic Updates: Part II

Antibiotic Updates: Part II Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures

More information

Clostridium difficile

Clostridium difficile Clostridium difficile A Challenge in Long-Term Care Andrew E. Simor, MD, FRCPC Sunnybrook Health Sciences Centre University of Toronto Hosted by Paul Webber paul@webbertraining.com Objectives to understand

More information

Guideline Updates Change is Inevitable Especially in Infectious Diseases!

Guideline Updates Change is Inevitable Especially in Infectious Diseases! Guideline Updates Change is Inevitable Especially in Infectious Diseases! Vicky Shah, PharmD, BCPS Assistant Professor of Pharmacy Practice Wilkes University Nesbitt School of Pharmacy 1 Vicky Shah has

More information

Preventing Clostridium difficile. July 13,

Preventing Clostridium difficile. July 13, Preventing Clostridium difficile Infection (CDI) July 13, 2011 1 Learning Objectives: Identify recent changes in the epidemiology of CDI, including transmission i and risk ikpopulations. Review recent

More information

C.difficile Re-emergence of an Old Pathogen

C.difficile Re-emergence of an Old Pathogen C.difficile Re-emergence of an Old Pathogen Gonzalo Bearman MD, MPH Assistant Professor of Medicine, Epidemiology and Community Health Associate Hospital Epidemiologist Virginia Commonwealth University

More information

GASTROINTESTINAL DISEASE IN THE HEALTHCARE SETTING: CLOSTRIDIUM DIFFICILE AND NOROVIRUS

GASTROINTESTINAL DISEASE IN THE HEALTHCARE SETTING: CLOSTRIDIUM DIFFICILE AND NOROVIRUS GASTROINTESTINAL DISEASE IN THE HEALTHCARE SETTING: CLOSTRIDIUM DIFFICILE AND NOROVIRUS Kerri A. Thom, MD, MS Assistant Professor, UM School of Medicine Associate Hospital Epidemiologist, UMMC DISCLOSURES

More information

Antibiotic therapy of acute gastroenteritis

Antibiotic therapy of acute gastroenteritis Antibiotic therapy of acute gastroenteritis Potential goals Clinical improvement (vs control) Fecal eradication of the pathogen and decrease infectivity Prevent complications Acute gastroenteritis viruses

More information

In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain

In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain J Antimicrob Chemother 2015; 70: 2311 2315 doi:10.1093/jac/dkv092 Advance Access publication 15 April 2015 In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium

More information

MAJOR ARTICLE. Antibiotic treatment is often associated with diarrhea and symptoms ranging from mild abdominal

MAJOR ARTICLE. Antibiotic treatment is often associated with diarrhea and symptoms ranging from mild abdominal MAJOR ARTICLE Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections Kathleen M. Mullane,

More information

Straight Poop about Clostridium difficile. Many Interesting Aspects. Endoscopic Appearance. Pseudomembranous Colitis (PMC)

Straight Poop about Clostridium difficile. Many Interesting Aspects. Endoscopic Appearance. Pseudomembranous Colitis (PMC) Straight Poop about Clostridium difficile Jon E. Lutz, M.D. Many Interesting Aspects History Pathology Bacteriology and cell biology Epidemiology Clinical manifestations Drug therapy Alternative therapies

More information

Incidence of hospital-acquired Clostridium difficile infection in patients at risk

Incidence of hospital-acquired Clostridium difficile infection in patients at risk Baptist Health South Florida Scholarly Commons @ Baptist Health South Florida All Publications 5-20-2016 Incidence of hospital-acquired Clostridium difficile infection in patients at risk Christine Ibarra

More information

UPDATES IN INFECTIOUS DISEASES

UPDATES IN INFECTIOUS DISEASES Disclosures UPDATES IN INFECTIOUS DISEASES Nothing to disclose Jacob Kesner, PharmD Lovelace Medical Center Albuquerque, NM 2018 NMSHP Balloon Fiesta Symposium Objectives Outline Pharmacist: 1. Recall

More information

Get Your. A Midday Symposium and Live Webinar conducted at the 2018 Midyear Clinical Meeting and Exhibition

Get Your. A Midday Symposium and Live Webinar conducted at the 2018 Midyear Clinical Meeting and Exhibition Get Your CE IN THE MIDDAY A Midday Symposium and Live Webinar conducted at the 2018 Midyear Clinical Meeting and Exhibition Improving the Lives of Patients with Clostridium Difficile Infection Monday,

More information

Antibiotic Updates: Part I

Antibiotic Updates: Part I Antibiotic Updates: Part I Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures

More information

Newsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017

Newsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017 Newsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017 Newsflash: Fluoroquinolones Newsflash: Fluoroquinolones Don t

More information

UPDATES IN INFECTIOUS DISEASES

UPDATES IN INFECTIOUS DISEASES UPDATES IN INFECTIOUS DISEASES Jacob Kesner, PharmD Lovelace Medical Center Albuquerque, NM 2018 NMSHP Balloon Fiesta Symposium Disclosures Nothing to disclose 1 Objectives Pharmacist: 1. Recall infectious

More information

Antimicrobial Stewardship

Antimicrobial Stewardship Antimicrobial Stewardship Preventing the Spread of Antibiotic Resistance and Improving Patient Care (Adapted from the Centers for Disease Control and Prevention) What is Stewardship? Antimicrobial stewardship

More information

Community-Associated C. difficile Infection: Think Outside the Hospital. Maria Bye, MPH Epidemiologist May 1, 2018

Community-Associated C. difficile Infection: Think Outside the Hospital. Maria Bye, MPH Epidemiologist May 1, 2018 Community-Associated C. difficile Infection: Think Outside the Hospital Maria Bye, MPH Epidemiologist Maria.Bye@state.mn.us 651-201-4085 May 1, 2018 Clostridium difficile Clostridium difficile Clostridium

More information

Running head: CLOSTRIDIUM DIFFICILE 1

Running head: CLOSTRIDIUM DIFFICILE 1 Running head: CLOSTRIDIUM DIFFICILE 1 Clostridium difficile Infection Christy Lee Fenton Mountainland Applied Technology College CLOSTRIDIUM DIFFICILE 2 Clostridium difficile Infection Approximately 200,000

More information

Antibiotic Stewardship in LTC What does this mean?

Antibiotic Stewardship in LTC What does this mean? Antibiotic Stewardship in LTC What does this mean? Kieran Moore FCFP,FRCPC, Diane Lu CCFP KFLA Public Health Disclosure The findings and conclusions represent those of the presenter and may not necessarily

More information

Antimicrobial Prescribing Advice for patients with Clostridium difficile Associated Diarrhoea

Antimicrobial Prescribing Advice for patients with Clostridium difficile Associated Diarrhoea For use in: By: For: Antimicrobial Prescribing Advice for patients with Clostridium difficile Division responsible for document: Key words: Names of document authors: Job titles of document authors: Name

More information

ANTIMICROBIAL STEWARDSHIP: ADVANCING PATIENT CARE BY IMPROVING MEDICATION USE

ANTIMICROBIAL STEWARDSHIP: ADVANCING PATIENT CARE BY IMPROVING MEDICATION USE ANTIMICROBIAL STEWARDSHIP: ADVANCING PATIENT CARE BY IMPROVING MEDICATION USE ANTHONY M. CASAPAO, PHARM.D. ASSISTANT PROFESSOR OF PHARMACY PRACTICE HUSSON UNIVERSITY SCHOOL OF PHARMACY CLINICAL INFECTIOUS

More information

Antimicrobial stewardship: Quick, don t just do something! Stand there!

Antimicrobial stewardship: Quick, don t just do something! Stand there! Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger

More information

C Diff: The Latest Scope on

C Diff: The Latest Scope on C Diff: The Latest Scope on the Poop Kathleen M. Vollman MSN, RN, CCNS, FCCM, FAAN Clinical Nurse Specialist / Consultant ADVANCING NURSING kvollman@comcast.net Northville Michigan www.vollman.com ADVANCING

More information

Practical Pearls for Effective Sustainable Stewardship Programs

Practical Pearls for Effective Sustainable Stewardship Programs Practical Pearls for Effective Sustainable Stewardship Programs Promoting Antimicrobial Stewardship Programs in Minnesota Oct. 24 th, 2013 MOA Bloomington, MN Susan Kline, MD, MPH Introduction Lead Physician

More information

Antibiotic Stewardship in the Hospital Setting

Antibiotic Stewardship in the Hospital Setting Antibiotic Stewardship in the Hospital Setting G. Evans, MD FRCPC Medical Director, Infection Prevention & Control Kingston General Hospital & Hotel Dieu Hospital EOPIC September 26, 2012 Stewardship stew-ard-ship

More information

biomérieux, Inc. 100 Rodolphe Street Durham, NC U.S.A. Tel. : (800) Fax : (800)

biomérieux, Inc. 100 Rodolphe Street Durham, NC U.S.A. Tel. : (800) Fax : (800) 2014 BIOMÉRIEUX, INC. BIOMÉRIEUX, THE BLUE LOGO, EMPOWERING CLINICAL DECISIONS, API, CHROMID, DIVERSILAB, ETEST, VIDAS, VIGIGUARD, VITEK ARE USED PENDING AND/OR REGISTERED TRADEMARKS BELONGING TO BIOMÉRIEUX

More information

Neonatal Antibiotic Prophylaxis and Surgical Site Infection Adam C. Alder, MD MSCS Ryan Walk, MD UTSW and Children s Health Dallas, TX

Neonatal Antibiotic Prophylaxis and Surgical Site Infection Adam C. Alder, MD MSCS Ryan Walk, MD UTSW and Children s Health Dallas, TX Neonatal Antibiotic Prophylaxis and Surgical Site Infection Adam C. Alder, MD MSCS Ryan Walk, MD UTSW and Children s Health Dallas, TX Nothing to disclose Disclosures Objectives Review the current challenges

More information

Healthcare-associated Infections Annual Report

Healthcare-associated Infections Annual Report September 2014 Healthcare-associated Infections Annual Report 2009-2013 Summary Provincial Infection Control Newfoundland Labrador (PIC-NL) has collected data on inpatients and outpatients with healthcare-associated

More information

The Epidemiology Of Clostridium Difficile Infections Among Oncology Patients

The Epidemiology Of Clostridium Difficile Infections Among Oncology Patients Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Public Health Theses School of Public Health January 2015 The Epidemiology Of Clostridium Difficile Infections Among Oncology

More information

11/22/2016. Antimicrobial Stewardship Update Disclosures. Outline. No conflicts of interest to disclose

11/22/2016. Antimicrobial Stewardship Update Disclosures. Outline. No conflicts of interest to disclose Antimicrobial Stewardship Update 2016 APIC-CI Conference November 17 th, 2016 Jay R. McDonald, MD Chief, ID Section VA St. Louis Health Care System Assistant Professor of medicine Washington University

More information

Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?

Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control and

More information

Protecting Patients and Antimicrobials Best Practices in Stewardship

Protecting Patients and Antimicrobials Best Practices in Stewardship Protecting Patients and Antimicrobials Best Practices in Stewardship Jonathan Hand MD Director, Antimicrobial Stewardship Program Director, Transplant Infectious Diseases Department of Infectious Diseases

More information

Implementation of a Clinical Decision Support Alert for the Management of Clostridium difficile Infection

Implementation of a Clinical Decision Support Alert for the Management of Clostridium difficile Infection Antibiotics 2015, 4, 667-674; doi:10.3390/antibiotics4040667 Article OPEN ACCESS antibiotics ISSN 2079-6382 www.mdpi.com/journal/antibiotics Implementation of a Clinical Decision Support Alert for the

More information

Clostridium difficile Infection

Clostridium difficile Infection The new england journal of medicine Review Article Dan L. Longo, M.D., Editor Clostridium difficile Infection Daniel A. Leffler, M.D., and J. Thomas Lamont, M.D. C lostridium difficile is an anaerobic

More information

Treatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days

Treatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days Treatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days Executive Summary National consensus guidelines created jointly by the Infectious Diseases Society of

More information

Clostridium difficile Surveillance Report 2016

Clostridium difficile Surveillance Report 2016 Clostridium difficile Surveillance Report 2016 EMERGING INFECTIONS PROGRAM Clostridium difficile Surveillance Report 2016 Minnesota Department of Health Emerging Infections Program PO Box 64882, St. Paul,

More information

3/20/2011. Code 215 of Hammurabi: If a physician performed a major operation on

3/20/2011. Code 215 of Hammurabi: If a physician performed a major operation on The Good Antibiotics: the Good, the Bad and the Ugly John P. Cello, MD Professor of Medicine and Surgery, University of California, San Francisco Most organisms can be readily identified by culture, special

More information

Clinical Inertia. Infectious Disease Update: Clostridium Difficile and Lyme Disease. Objectives. Guidelines for Antimicrobial Stewardship.

Clinical Inertia. Infectious Disease Update: Clostridium Difficile and Lyme Disease. Objectives. Guidelines for Antimicrobial Stewardship. Infectious Disease Update: Clostridium Difficile and Lyme Disease Jody Agins MSN, RNP, FNP/GNP-BC Collaborative Medical Provider Group PLLC jodyjfk@gotpharm.com Objectives Recognize the growing incidence,

More information

Alfonso Torress-Cook, Dr.P.H. Director of Epidemiology/Patient Safety Pacific Hospital of Long Beach

Alfonso Torress-Cook, Dr.P.H. Director of Epidemiology/Patient Safety Pacific Hospital of Long Beach Alfonso Torress-Cook, Dr.P.H. Director of Epidemiology/Patient Safety Pacific Hospital of Long Beach Historical overview The myriad causes of hospital acquired diarrhea Microbiology and ecology of Clostridium

More information

Infection Control of Emerging Diseases

Infection Control of Emerging Diseases 2016 EPS Training Event Martin E. Evans, MD Director, VHA MDRO Program National Infectious Diseases Service Lexington, KY & Cincinnati, OH Infection Control of Emerging Diseases 2016 EPS Training Event

More information

INFECTIOUS DISEASES STRATEGIES TO LIMIT HOSPITALIZATION,REDUCE RISK AND ADD VALUE

INFECTIOUS DISEASES STRATEGIES TO LIMIT HOSPITALIZATION,REDUCE RISK AND ADD VALUE INFECTIOUS DISEASES STRATEGIES TO LIMIT HOSPITALIZATION,REDUCE RISK AND ADD VALUE Ronald G Nahass, MD, MHCM, FIDSA President ID CARE Clinical Professor of Medicine-Rutgers University Robert Wood Johnson

More information

Skin and Soft Tissue Infections Emerging Therapies and 5 things to know

Skin and Soft Tissue Infections Emerging Therapies and 5 things to know 2011 MFMER slide-1 Skin and Soft Tissue Infections Emerging Therapies and 5 things to know Aaron Tande, MD Assistant Professor of Medicine October 27, 2017 Division of INFECTIOUS DISEASES 2011 MFMER slide-2

More information

Top Ten Articles Infection Prevention and Control

Top Ten Articles Infection Prevention and Control Top Ten Articles Infection Prevention and Control 2017-2018 John M Conly MD Chingiz Amirov Just wash em! May 2018 Objectives Research or evidence-based guidelines in IPC Critique strengths and weaknesses

More information

Prevention of Endemic Healthcare-Associated Clostridium difficile Infection: Reviewing the Evidence

Prevention of Endemic Healthcare-Associated Clostridium difficile Infection: Reviewing the Evidence CLINICAL AND SYSTEMATIC S nature publishing group 2327 CME Prevention of Endemic Healthcare-Associated Clostridium difficile Infection: Reviewing the Evidence J. Hsu, MD 1, C. Ab a d, M D 1, M. D i n h,

More information

THE HUMAN MICROBIOME: THE INFECTION PREVENTIONIST S BEST FRIEND

THE HUMAN MICROBIOME: THE INFECTION PREVENTIONIST S BEST FRIEND THE HUMAN MICROBIOME: THE INFECTION PREVENTIONIST S BEST FRIEND Michigan Communicable Disease Conference May 4, 2017 Richard A. Van Enk, Ph.D., CIC Director, Infection Prevention and Epidemiology vanenkr@bronsonhg.org

More information

Antibiotic Stewardship at MetroWest Medical Center. Colleen Grocer, RPh, BCOP Co-Chair, Antibiotic Stewardship Committee

Antibiotic Stewardship at MetroWest Medical Center. Colleen Grocer, RPh, BCOP Co-Chair, Antibiotic Stewardship Committee Antibiotic Stewardship at MetroWest Medical Center Colleen Grocer, RPh, BCOP Co-Chair, Antibiotic Stewardship Committee Antibiotic Stewardship Committee Subcommittee of Pharmacy and Therapeutics. Also

More information

Healthcare-associated Infections Annual Report March 2015

Healthcare-associated Infections Annual Report March 2015 March 2015 Healthcare-associated Infections Annual Report 2009-2014 TABLE OF CONTENTS SUMMARY... 1 MRSA SURVEILLANCE RESULTS... 1 CDI SURVEILLANCE RESULTS... 1 INTRODUCTION... 2 METHICILLIN-RESISTANT

More information

Nosocomial Infections: What Are the Unmet Needs

Nosocomial Infections: What Are the Unmet Needs Nosocomial Infections: What Are the Unmet Needs Jean Chastre, MD Service de Réanimation Médicale Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris 6, France www.reamedpitie.com

More information

2010 ARO/CDI Prevalence Survey. MRSA [ ] VRE [ ] Clostridium difficile [ ]

2010 ARO/CDI Prevalence Survey. MRSA [ ] VRE [ ] Clostridium difficile [ ] 2010 ARO/CDI Prevalence Survey 1) Patient identifier: 2) Hospital number: 3) Is the patient currently (day of survey) infected or colonized with (check all that apply): MRSA [ ] VRE [ ] Clostridium difficile

More information

New Antibiotics for MRSA

New Antibiotics for MRSA New Antibiotics for MRSA Faculty Warren S. Joseph, DPM, FIDSA Consultant, Lower Extremity Infectious Diseases Roxborough Memorial Hospital Philadelphia, Pennsylvania Faculty Disclosure Dr. Joseph: Speaker

More information

Healthcare-associated Infections Annual Report December 2018

Healthcare-associated Infections Annual Report December 2018 December 2018 Healthcare-associated Infections Annual Report 2011-2017 TABLE OF CONTENTS INTRODUCTION... 1 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS... 2 MRSA SURVEILLANCE... 3 CLOSTRIDIUM

More information

Optimize Durations of Antimicrobial Therapy

Optimize Durations of Antimicrobial Therapy Optimize Durations of Antimicrobial Therapy Evidence & Application Jill Cowper, Pharm.D. Division Infectious Diseases Pharmacist Parallon Supply Chain Solutions Richmond, VA P: 607 221 5101 jill.butterfield@parallon.com

More information

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University

More information

Georgia State University. Georgia State University. Zirka Thompson. Spring

Georgia State University. Georgia State University. Zirka Thompson. Spring Georgia State University ScholarWorks @ Georgia State University Public Health Theses School of Public Health Spring 5-11-2012 Comparison of Risk Factors for Clostridium Difficile Infection Among Community

More information

Antibiotic Stewardship

Antibiotic Stewardship Antibiotic Stewardship Nick Zaksek Pharm D., BCPS AQ-ID Infectious Disease POMA 2019 1 Disclosures None 2 Objectives Practice good Antibiotic stewardship and foster the notion of antibiotic stewardship

More information

Why Antimicrobial Stewardship?

Why Antimicrobial Stewardship? Antimicrobial Stewardship: Why and How CAPT Arjun Srinivasan, MD Associate Director for Healthcare Associated Infection Prevention Programs Division of Healthcare Quality Promotion Why Antimicrobial Stewardship?

More information

Infectious Disease in PA/LTC an Update. Karyn P. Leible, MD, CMD, FACP October 2015

Infectious Disease in PA/LTC an Update. Karyn P. Leible, MD, CMD, FACP October 2015 Infectious Disease in PA/LTC an Update Karyn P. Leible, MD, CMD, FACP October 2015 Disclosures Dr. Leible has no financial disclosures relevant to this presentation. Introduction Objectives The participant

More information

(c) 2016, Freeman et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

(c) 2016, Freeman et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. This is a repository copy of In vitro activities of MCB3681 and 8 comparators against Clostridium difficile isolates with known ribotypes and diverse geographical spread. White Rose Research Online URL

More information

Antibiotics in the trenches: An ER Doc s Perspective

Antibiotics in the trenches: An ER Doc s Perspective Antibiotics in the trenches: An ER Doc s Perspective Peter Currie, MD Medical Director for Quality Emergency Physicians Professional Association (EPPA) Agenda Emergency Medicine Specific Disease Processes

More information

Clostridium difficile may be found in 1% to 3% of all

Clostridium difficile may be found in 1% to 3% of all ORIGINAL ARTICLE Evaluating contemporary antibiotics as a risk factor for Clostridium difficile infection in surgical trauma patients Kruti Shah, PharmD, BCPS, Leigh Ann Pass, PharmD, BCPS, Mark Cox, PharmD,

More information

Overcoming Barriers to Antimicrobial Stewardship

Overcoming Barriers to Antimicrobial Stewardship Overcoming Barriers to Antimicrobial Stewardship New guidelines and core elements Learning Objectives: 1) Establish common definitions of infectious and antibiotic stewardship terminology. 2) Define and

More information

Le infezioni di cute e tessuti molli

Le infezioni di cute e tessuti molli Le infezioni di cute e tessuti molli SCELTE e STRATEGIE TERAPEUTICHE Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Treatment of complicated skin and skin structure infections

More information

ANTIMICROBIAL THERAPY AND CLOSTRIDIUM DIFFICILE INFECTION

ANTIMICROBIAL THERAPY AND CLOSTRIDIUM DIFFICILE INFECTION ANTIMICROBIAL THERAPY AND CLOSTRIDIUM DIFFICILE INFECTION 1 Olariu T, 1* Nicolescu A, 2 Chiorean A, 3 Dunca E, 4 Negru D, Olariu I 1 Vasile Goldis Western University of Arad, Department of Intensive Care,

More information

Antibiotic Stewardship in the Neonatal Intensive Care Unit. Objectives. Background 4/20/2017. Natasha Nakra, MD April 28, 2017

Antibiotic Stewardship in the Neonatal Intensive Care Unit. Objectives. Background 4/20/2017. Natasha Nakra, MD April 28, 2017 Antibiotic Stewardship in the Neonatal Intensive Care Unit Natasha Nakra, MD April 28, 2017 Objectives 1. Describe antibiotic use in the NICU 2. Explain the role of antibiotic stewardship in the NICU 3.

More information

Role of the general physician in the management of sepsis and antibiotic stewardship

Role of the general physician in the management of sepsis and antibiotic stewardship Role of the general physician in the management of sepsis and antibiotic stewardship Prof Martin Wiselka Dept of Infection and Tropical Medicine University Hospitals of Leicester Sepsis and antibiotic

More information

Duration of antibiotic therapy:

Duration of antibiotic therapy: Duration of antibiotic therapy: How low can you go? Thomas Holland, MD Hilton Head, SC July 2017 Disclosures Consulting: The Medicines Company, Basilea Pharmaceutica Adjudication committee: Achaogen Grant

More information

Antibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco

Antibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco Antibacterial Resistance: Research Efforts Henry F. Chambers, MD Professor of Medicine University of California San Francisco Resistance Resistance Dose-Response Curve Antibiotic Exposure Anti-Resistance

More information

Antimicrobial Stewardship 101

Antimicrobial Stewardship 101 Antimicrobial Stewardship 101 Betty P. Lee, Pharm.D. Pediatric Infectious Disease/Antimicrobial Stewardship Pharmacist Lucile Packard Children s Hospital Stanford Disclosure I have no actual or potential

More information

MDRO s, Stewardship and Beyond. Linda R. Greene RN, MPS, CIC

MDRO s, Stewardship and Beyond. Linda R. Greene RN, MPS, CIC MDRO s, Stewardship and Beyond Linda R. Greene RN, MPS, CIC linda_greene@urmc.rochester.edu Evolving Threat of Antimicrobial Resistance Why are MDROs important? Limited treatment options Associated with:

More information

Antimicrobial stewardship in managing septic patients

Antimicrobial stewardship in managing septic patients Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest

More information

IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP)

IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP) IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP) Lucas Schonsberg, PharmD PGY-1 Pharmacy Practice Resident Providence St. Patrick Hospital Missoula,

More information

Geriatric Mental Health Partnership

Geriatric Mental Health Partnership Geriatric Mental Health Partnership September 8, 2017 First, let s test your knowledge about antibiotics http://www.cdc.gov/getsmart/community/about/quiz.html 2 Get Smart Antibiotics Quiz Antibiotics fight

More information

5/15/17. Core Elements of Outpatient Antibiotic Stewardship: Implementing Antibiotic Stewardship Into Your Outpatient Practice.

5/15/17. Core Elements of Outpatient Antibiotic Stewardship: Implementing Antibiotic Stewardship Into Your Outpatient Practice. National Center for Emerging and Zoonotic Infectious Diseases Core Elements of Outpatient Antibiotic Stewardship: Implementing Antibiotic Stewardship Into Your Outpatient Practice Melinda Neuhauser, PharmD,

More information

CONFLICT OF INTEREST ANTIMICROBIAL LOCK SOLUTIONS INCREASE BACTEREMIA

CONFLICT OF INTEREST ANTIMICROBIAL LOCK SOLUTIONS INCREASE BACTEREMIA CONFLICT OF INTEREST ANTIMICROBIAL LOCK SOLUTIONS INCREASE BACTEREMIA NONE Vandana Dua Niyyar, MD Associate Professor of Medicine, Division of Nephrology, Emory University. OBJECTIVES Role of biofilm in

More information

MAGNITUDE OF ANTIMICROBIAL USE. Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges

MAGNITUDE OF ANTIMICROBIAL USE. Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control

More information

Current Trends in Antimicrobial Resistance and Need for Antimicrobial Stewardship Among Urologists. Edward A. Stenehjem, MD

Current Trends in Antimicrobial Resistance and Need for Antimicrobial Stewardship Among Urologists. Edward A. Stenehjem, MD Current Trends in Antimicrobial Resistance and Need for Antimicrobial Stewardship Among Urologists Edward A. Stenehjem, MD Director, Antibiotic Stewardship, Urban Central Region, Department of Clinical

More information